<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="2110">
  <stage>Registered</stage>
  <submitdate>18/09/2008</submitdate>
  <approvaldate>18/09/2008</approvaldate>
  <nctid>NCT00756600</nctid>
  <trial_identification>
    <studytitle>A Multi-site Randomized Controlled Trial Comparing Regional and General Anesthesia for Effects on Neurodevelopmental Outcome and Apnea in Infants</studytitle>
    <scientifictitle>A Multi-site Randomised Controlled Trial Comparing Regional and General Anaesthesia for Effects on Neurodevelopmental Outcome and Apnoea in Infants</scientifictitle>
    <utrn />
    <trialacronym>GAS</trialacronym>
    <secondaryid>06-07-0320</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Inguinal Hernia</healthcondition>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - Regional Anesthesia
Treatment: drugs - General Anesthesia

Active Comparator: 1 - Regional Anesthesia

Active Comparator: 2 - General Anesthesia


Treatment: drugs: Regional Anesthesia
Up to 2.5 mg/kg bupivacaine administered by caudal or subarachnoid routes or both caudal and subarachnoid or subarachnoid and ilioinguinal nerve blockade. Single shot.

Treatment: drugs: General Anesthesia
Sevoflurane for induction and maintenance of general anesthesia, dose up to 8% inspired for duration of procedure plus bupivacaine local anesthetic blockade (up to 2.5 mg/kg) administered via caudal or ilioinguinal nerve block.

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>The primary outcome will be the Wechsler Preschool and Primary Scale of Intelligence-Third Edition (WPPSI-III)full scale IQ score.</outcome>
      <timepoint>At 5 years chronological age</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Bayley neurodevelopmental scale. Also, frequency and characteristics of apnea in the post-operative period.</outcome>
      <timepoint>At 2 years corrected age.</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Any infant scheduled for unilateral or bilateral inguinal hernia repair (with or
             without circumcision)

          -  Any infant whose gestational age is 26 weeks or more (GA = 182 days)

          -  Any infant whose post-menstrual age is up to 60 weeks (PMA = 426 days)</inclusivecriteria>
    <inclusiveminage />
    <inclusiveminagetype>No limit</inclusiveminagetype>
    <inclusivemaxage>60</inclusivemaxage>
    <inclusivemaxagetype>Weeks</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Any child older than 60 weeks post-menstrual age

          -  Any child born less than 26 weeks gestation

          -  Any contraindication to general or spinal/caudal anesthesia (for example:
             neuromuscular disorder or coagulopathy)

          -  Pre-operative ventilation immediately prior to surgery

          -  Congenital heart disease that has required ongoing pharmacotherapy

          -  Known chromosomal abnormality or any other known acquired or congenital abnormalities
             (apart from prematurity) which are likely to affect development

          -  Children where follow-up would be difficult for geographic or social reasons

          -  Families where English is not the primary language spoken at home

          -  Known neurological injury such as cystic periventricular leukomalacia (PVL), or grade
             3 or 4 intra ventricular hemorrhage (ICH) (+/- post hemorrhage ventricular dilation)

          -  Previous exposure to volatile anesthesia or benzodiazepines as a neonate or in the
             third trimester in utero.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3>The people assessing the outcomes</masking3>
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 4</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2006</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>720</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Active, not recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/01/2018</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>SA,VIC,WA</recruitmentstate>
    <hospital>Adelaide Women's and Children's Hospital - North Adelaide</hospital>
    <hospital>Casey Hospital - Berwick</hospital>
    <hospital>Monash Medical Centre - Clayton</hospital>
    <hospital>Cabrini Hospital - Malvern</hospital>
    <hospital>Royal Children's Hospital - Parkville</hospital>
    <hospital>Princess Margaret Hospital - Perth</hospital>
    <postcode>5006 - North Adelaide</postcode>
    <postcode>3806 - Berwick</postcode>
    <postcode>3165 - Clayton</postcode>
    <postcode>3144 - Malvern</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>6008 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Iowa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Hampshire</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Tennessee</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Vermont</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Canada</country>
      <state>Quebec</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bergamo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Genoa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Groningen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Netherlands</country>
      <state>Utrecht</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Glasgow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Belfast</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Birmingham</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Bristol</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Liverpool</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United Kingdom</country>
      <state>Sheffield</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Other</primarysponsortype>
    <primarysponsorname>Boston Childrenâ€™s Hospital</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Royal Children's Hospital</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Royal Hospital for Sick Children</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Other</othercollaboratortype>
      <othercollaboratorname>Murdoch Childrens Research Institute</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
    <othercollaborator>
      <othercollaboratortype>Government body</othercollaboratortype>
      <othercollaboratorname>Food and Drug Administration (FDA)</othercollaboratorname>
      <othercollaboratoraddress />
      <othercollaboratorcountry />
    </othercollaborator>
  </sponsorship>
  <ethicsAndSummary>
    <summary>The primary purpose of the GAS study is to determine whether different types of anesthesia
      (Regional versus General) given to 720 infants undergoing inguinal hernia repair results in
      equivalent neurodevelopmental outcomes. The study also aims to describe the incidence of
      apnea in the post-operative period after both regional and general anesthesia for inguinal
      hernia repair in infants. This study is important as it will provide the greatest evidence
      for safety or toxicity of general anesthesia for human infants.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT00756600</trialwebsite>
    <publication>Davidson A, McCann ME, Morton N. Anesthesia neurotoxicity in neonates: the need for clinical research. Anesth Analg. 2007 Sep;105(3):881-2.
</publication>
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Andrew Davidson, MD</name>
      <address>Royal Children's Hospital, Victoria, Australia</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>